The capacity expansion and referral growth signal potential near-term revenue acceleration. Traders should watch for the next quarterly filing (10-Q) for actual revenue contribution from the new facility and monitor any additional financing needs given the company's $6M market cap.
Price Chart
Executive Summary
Vivos Therapeutics announced the grand opening of a new sleep testing and treatment facility in Henderson, Nevada, expected to more than double annual revenue production capacity to over $10 million. The company reports that incoming referrals in the Las Vegas market have more than doubled since May-June, suggesting strong demand. This is a forward-looking operational expansion with no current financial results disclosed, making it a notable but unconfirmed growth catalyst for a micro-cap stock.
Key Facts
- New Henderson, Nevada facility grand opening on August 27, 2026.
- Company expects the new facility to more than double annual production capacity to over $10 million.
- Total incoming referrals in the Las Vegas market have more than doubled since the May-June timeframe.
- Facility expected to employ up to 30 personnel at full capacity.
- Filing is an 8-K under Item 7.01 (Regulation FD Disclosure) — press release furnished, not filed.
Financial Impact
Expected to more than double annual revenue production capacity to over $10 million in Henderson, Nevada.
Risk Factors
- Forward-looking statements only — no actual revenue or patient volume data provided.
- Micro-cap company ($6M market cap) with limited operating history and potential need for additional financing.
- Risk that increased referrals may not translate into revenue, or that the company cannot staff the facility as planned.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (VVOS) — Batch item 1 | 0001493152-26-039736 |
| Exhibit: ex99-1.htm | 0001493152-26-039736 |
| Document: 0001493152-26-039736-index-headers.html | 0001493152-26-039736 |
| Document: 0001493152-26-039736-index.html | 0001493152-26-039736 |
| Document: 0001493152-26-039736.txt | 0001493152-26-039736 |
| 8-K Filing (VVOS) — Batch item 6 | 0001493152-26-039736 |
| Exhibit: ex99-1.htm | 0001493152-26-039736 |
| Document: 0001493152-26-039736-index-headers.html | 0001493152-26-039736 |
| Document: 0001493152-26-039736-index.html | 0001493152-26-039736 |
| Document: 0001493152-26-039736.txt | 0001493152-26-039736 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1310 (−2.75%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1310 (−7.09%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1310 (−6.83%) |
Oct 15, 2026 11d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1310 (−8.26%) |
Oct 15, 2026 11d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1310 (−8.26%) |
Sep 30, 2026 26d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1310 (+12.08%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1310 (−41.75%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1310 (−52.67%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1310 (+56.51%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1310 (−61.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers